DK0691404T3 - Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf - Google Patents

Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf

Info

Publication number
DK0691404T3
DK0691404T3 DK95890132T DK95890132T DK0691404T3 DK 0691404 T3 DK0691404 T3 DK 0691404T3 DK 95890132 T DK95890132 T DK 95890132T DK 95890132 T DK95890132 T DK 95890132T DK 0691404 T3 DK0691404 T3 DK 0691404T3
Authority
DK
Denmark
Prior art keywords
vaccine
preparation
well
virus infections
immunization against
Prior art date
Application number
DK95890132T
Other languages
English (en)
Inventor
Xaver Prof Dr Heinz Franz
Dr Allison Steven
Doz Dr Mandl Christian
Prof Dr Kunz Christian
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0135294A external-priority patent/AT402897B/de
Priority claimed from AT0087195A external-priority patent/AT405607B/de
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0691404T3 publication Critical patent/DK0691404T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK95890132T 1994-07-08 1995-07-06 Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf DK0691404T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0135294A AT402897B (de) 1994-07-08 1994-07-08 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT0087195A AT405607B (de) 1995-05-23 1995-05-23 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung

Publications (1)

Publication Number Publication Date
DK0691404T3 true DK0691404T3 (da) 2001-03-19

Family

ID=25594155

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98107383T DK0869184T3 (da) 1994-07-08 1995-07-06 Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
DK95890132T DK0691404T3 (da) 1994-07-08 1995-07-06 Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK98107383T DK0869184T3 (da) 1994-07-08 1995-07-06 Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf

Country Status (9)

Country Link
EP (2) EP0691404B1 (da)
AT (2) ATE198909T1 (da)
CZ (1) CZ282927B6 (da)
DE (2) DE59508988D1 (da)
DK (2) DK0869184T3 (da)
ES (2) ES2165109T3 (da)
FI (2) FI117974B (da)
HU (2) HU219503B (da)
RU (1) RU2150294C1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047448B1 (en) * 1997-11-20 2006-02-01 United States Army Medical Research and Materiel Command Dna vaccines against tick-borne flaviviruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
WO2003102166A2 (en) 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
DK2027155T3 (da) 2006-06-06 2016-05-09 Crucell Holland Bv Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf
CA2703519C (en) 2007-11-09 2017-04-18 The Salk Institute For Biological Studies Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2074422T3 (es) * 1987-03-20 1995-09-16 Immuno Ag Moleculas de adn y arn del subtipo accidental del virus fsma, polipeptidos, que son codificados por estas moleculas, y su uso.
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus

Also Published As

Publication number Publication date
FI953371L (fi) 1996-01-09
HU219503B (hu) 2001-04-28
HUT72395A (en) 1996-04-29
HU9501832D0 (en) 1995-08-28
ATE198909T1 (de) 2001-02-15
EP0691404A3 (de) 1997-11-12
DE59508988D1 (de) 2001-03-01
RU2150294C1 (ru) 2000-06-10
FI117974B (fi) 2007-05-15
HU224199B1 (hu) 2005-06-28
EP0691404A2 (de) 1996-01-10
ES2155510T3 (es) 2001-05-16
EP0869184B1 (de) 2001-10-04
FI118222B (fi) 2007-08-31
EP0691404B1 (de) 2001-01-24
DK0869184T3 (da) 2001-12-17
CZ282927B6 (cs) 1997-11-12
ES2165109T3 (es) 2002-03-01
ATE206459T1 (de) 2001-10-15
HU9903233D0 (en) 1999-11-29
EP0869184A3 (de) 1999-05-12
FI953371A0 (fi) 1995-07-07
DE59509667D1 (de) 2001-11-08
FI20070041L (fi) 2007-01-17
CZ176995A3 (en) 1996-01-17
EP0869184A2 (de) 1998-10-07

Similar Documents

Publication Publication Date Title
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
FI943591A7 (fi) Synteettinen hemofilus-influenssa yhdistelmärokote
DE58906121D1 (de) Rekombinantes Vaccinia-Virus MVA.
EP1847549A3 (en) Papillomavirus polyprotein constructs
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
AU580059B2 (en) Vaccine against rabies and preparation process thereof
ATE215124T1 (de) Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
HUT71847A (en) Dna molecules encoding aminopeptidase enzymes, vectors and transgenic cells containing dna molecules, immunogenic polypeptides encoding by dna molecules, vaccines against helminth infections containing these peptides and process for the preparation ...
WO2002062296A3 (en) Methods and compositions useful for stimulating an immune response
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
CY1105600T1 (el) Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση
ATE346931T1 (de) Clostridium perfringens impfstoff
DK0869184T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
DK457687A (da) Antigenisk aktive proteiner og peptider, og vacciner mod virus for felin peritonitis (fipv) med indhold af saadanne proteiner eller peptider
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
DK0778894T3 (da) Vaccine mod infektiös felin peritonitis
PT729509E (pt) Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
ZA896942B (en) Allelic variants of plasmodium falciparum merozoite surface antigen
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.